Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00722007
Other study ID # Cormet (P050016) New Enroll
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 24, 2008
Est. completion date May 12, 2014

Study information

Verified date May 2019
Source Corin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the performance of the Cormet Hip Resurfacing implant system in the post-approval environment.


Description:

This study tracks the performance of the Cormet Hip Resurfacing system in the post-approval environment to see if there are significant changes in device performance from the pre-market IDE setting as compared to the post-approval setting. Specifically this study will compare the proportion of subjects achieving a Month 24 composite clinical success (CCS) criterion and 24 month cumulative revision rate among the newly enrolled post-approval study subjects to the IDE subjects' performance on CCS as reported in the Pre-Market Application (PMA).


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date May 12, 2014
Est. primary completion date April 11, 2014
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Male or female patient who meets eligibility criteria consistent with product labeling

- skeletally mature

- mentally capable of completing follow-up forms

- Will be available for follow-up out to 2 years and annually thereafter until the last patient reaches the two-year evaluation

- Has been deemed a candidate for hip replacement by diagnosis of the investigator

- consented to participate in the clinical study

Exclusion Criteria:

- Patient with active or suspected infection in or around the hip joint;

- Patient with bone stock inadequate to support the device

- Patient with severe osteopenia

- Patient with a family history of severe osteoporosis or severe osteopenia;

- Patient with osteonecrosis or avascular necrosis (AVN) with >50% involvement of the femoral head (regardless of FICAT Grade)

- Patient with multiple cysts of the femoral head (>1cm)

- In cases of questionable bone stock, a DEXA scan may be necessary to assess inadequate bone stock.

- Patient with any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery;

- Female of child-bearing age due to unknown effects on the fetus of metal ion release.

- Patient with known moderate or severe renal insufficiency;

- Patient who is immunosuppressed with diseases such as AIDS or person receiving high doses of corticosteroids;

- Patient who is severely overweight;

- Patient with known or suspected metal sensitivity (e.g., jewelry).

Study Design


Intervention

Device:
Cormet Hip Resurfacing
Cormet Hip Resurfacing implant

Locations

Country Name City State
United States Sinai Hospital of Baltimore Baltimore Maryland
United States Memorial Bone and Joint Clinic Houston Texas
United States Lattimore Orthopaedics P.C. Rochester New York
United States Willamette Orthopedic Group LLC Salem Oregon
United States Florida Orthopaedic Institute Tampa Florida
United States George Washington University Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Corin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Unilateral Procedures Which Achieved Composite Clinical Success (CCS) at Month 24 Composite Clinical Success (CCS) is based upon the following:
There has been no revision, removal, or replacement of any device component on or prior to the exact 24 month anniversary (i.e., relative day 730); and Month 24 Harris Hip Total score (HHS) = 80 points.
Month 24+
Secondary Number of Implants (Unilateral & Bilateral) With Harris Hip Scores (HHS) Components Including Total, Pain & Function Scored at Month 24+ All unilateral and bilateral implants have been assessed using the following grading:
Total HHS: Excellent (90-100); Good (80-89); Fair (70-79); Poor (<70) Pain HHS: None; Slight; Mild; Moderate; Marked; Totally Disabled Function HHS: Normal (40-47); Mild Dysfunction (30=<39); Moderate Dysfunction (20=<29); Severe Dysfunction (10=<19); Disabled (0=<9)
Month 24+
Secondary Survival Rate Using Kaplan-Meier Survival Curves Kaplan-Meier survival curves were completed for all implants (unilateral & bilateral) for Month 24 Month 24+
Secondary Number of Procedures (Unilateral & Bilateral) With Any Device Related Adverse Events Month 24+
Secondary The Number of Procedures (Unilateral & Bilateral) With Any Radiographic Findings at Month 24 Post Operatively The following was assessed:
Radiolucency Acetabular Component: I; II; III Radiolucency Femoral Component: Superior; Tip; Inferior Cup Migration and Tilt: Superior/Inferior Migration > 4mm; Medial/Lateral Migration > 4mm; Varus/Valgus Tilt > 4 degrees Stem Migration and Tilt: Subsidence of Femoral Component > 4mm and Stem tilting > 4 degrees Other Assessments: Anteversion of the Head = 5mm; Retroversion of the Head = 5 mm; Hypertrophy in Any Zone; Resorption in Any Zone; Lysis in Any Zone; Osteolysis
Month 24+
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4